2-oxothiatole compounds having activity as cpla2 inhibitors for the treatment of inflammatory disorders and hyperproliferative disorders

Abstract

A compound of formula (I′) wherein R 6 is H, C 1-6 alkyl, —(CH 2 ) p COOH, —(CH 2 ) p COOC 1-6 alkyl, —(CH 2 ) p CONH 2 , —(CH 2 ) p CONHC 1-6 alkyl, —(CH 2 ) p CON(C 1-6 alkyl) 2 , R 7 is as defined for R 6 ; or and R 7 taken together with the atoms joining them can form a 6 -membered aromatic or non aromatic, saturated or unsaturated, carbocyclic or heteroatom containing (e.g. O, N or S containing) ring optionally substituted by up to 4 groups R 8 ; each R 8 is defined as for R 6 or is oxo; R 10 is C 1-6 alkyl Ar is a C 6-14 aryl group, wherein the aryl group may be optionally substituted (preferably in the meta or para position relative to O) with one or more R 9 groups; each R 9 is halo, OH, CN, nitro, NH 2 , NHC 1-6 alkyl, N(C 1-6 alkyl) 2 , haloC 1-6 alkyl, C 6-10 aryl group, C 7-12 arylalkyl, a C 1-10 alkyl group, C 2-10 -mono or multiply unsaturated alkenyl group, OC 1-10 alkyl group, SC 1-10 alkyl group —OC 1-10 alkyl-O-C 10 alkyl , —C 1-10 alkykyl-O-C 1-10 alkyl, —OC 2-10 -mono or multiply unsaturated alkenyl group, OAr 2 , O(CH 2 ) q Ar 2 , SAr 2 or S(CH 2 ) q Ar 2 ; wherein Ar 2 is phenyl, optionally substituted with one or more of halo, trihalomethyl, C 1-10 -alkoxy, or C 1-10 alkyl; each q is 1 to 3, preferably 1; each p is 0 to 3; or a salt, ester, solvate, N-oxide, of prodrug thereof.

1 - 12 . (canceled) 
     
     
         13 . A compound of the formula below: 
       
         
           
           
               
               
           
         
         or a salt thereof. 
       
     
     
         14 . A pharmaceutical composition comprising a compound as claimed in  claim 13 . 
     
     
         15 . A method of treating a chronic inflammatory condition or hyperproliferative disorder in a patient comprising administering to the patient in need thereof an effective amount of a compound as claimed in  claim 13 .